Published in BMC Cancer on November 21, 2012
miR-204 mediated loss of Myeloid cell leukemia-1 results in pancreatic cancer cell death. Mol Cancer (2013) 1.04
The novel BH3 α-helix mimetic JY-1-106 induces apoptosis in a subset of cancer cells (lung cancer, colon cancer and mesothelioma) by disrupting Bcl-xL and Mcl-1 protein-protein interactions with Bak. Mol Cancer (2013) 1.04
USP9X expression correlates with tumor progression and poor prognosis in esophageal squamous cell carcinoma. Diagn Pathol (2013) 1.00
Regulation of Bim in Health and Disease. Oncotarget (2015) 0.95
La FAM fatale: USP9X in development and disease. Cell Mol Life Sci (2015) 0.92
Context-dependent function of the deubiquitinating enzyme USP9X in pancreatic ductal adenocarcinoma. Cancer Biol Ther (2014) 0.86
HSP90 inhibitor NVP-AUY922 enhances TRAIL-induced apoptosis by suppressing the JAK2-STAT3-Mcl-1 signal transduction pathway in colorectal cancer cells. Cell Signal (2014) 0.84
Inhibition of deubiquitinases primes glioblastoma cells to apoptosis in vitro and in vivo. Oncotarget (2016) 0.82
Co-targeting of Cyclooxygenase-2 and FoxM1 is a viable strategy in inducing anticancer effects in colorectal cancer cells. Mol Cancer (2015) 0.81
Molecular pathways: turning proteasomal protein degradation into a unique treatment approach. Clin Cancer Res (2014) 0.80
Comparison of Nanostring nCounter® Data on FFPE Colon Cancer Samples and Affymetrix Microarray Data on Matched Frozen Tissues. PLoS One (2016) 0.79
Kinase-Independent Small-Molecule Inhibition of JAK-STAT Signaling. J Am Chem Soc (2015) 0.78
Deubiquitylating enzyme USP9x regulates radiosensitivity in glioblastoma cells by Mcl-1-dependent and -independent mechanisms. Cell Death Dis (2016) 0.78
EHMT2 inhibitor BIX-01294 induces apoptosis through PMAIP1-USP9X-MCL1 axis in human bladder cancer cells. Cancer Cell Int (2015) 0.78
Degrasyn-like symmetrical compounds: possible therapeutic agents for multiple myeloma (MM-I). Bioorg Med Chem (2014) 0.78
Ubiquitin-specific proteases as therapeutic targets for the treatment of breast cancer. Breast Cancer Res (2014) 0.78
Naturally Occurring Isothiocyanates Exert Anticancer Effects by Inhibiting Deubiquitinating Enzymes. Cancer Res (2015) 0.78
Deubiquitinase inhibition by WP1130 leads to ULK1 aggregation and blockade of autophagy. Autophagy (2015) 0.77
Reduced ubiquitin-specific protease 9X expression induced by RNA interference inhibits the bioactivity of hepatocellular carcinoma cells. Oncol Lett (2015) 0.76
Inhibition of protein phosphatase 2A (PP2A) prevents Mcl-1 protein dephosphorylation at the Thr-163/Ser-159 phosphodegron, dramatically reducing expression in Mcl-1-amplified lymphoma cells. J Biol Chem (2014) 0.76
Arginine methylation of USP9X promotes its interaction with TDRD3 and its anti-apoptotic activities in breast cancer cells. Cell Discov (2017) 0.75
USP9X destabilizes pVHL and promotes cell proliferation. Oncotarget (2016) 0.75
Targeting the apoptotic Mcl-1-PUMA interface with a dual-acting compound. Oncotarget (2017) 0.75
The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell (2006) 10.19
Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell (2006) 8.59
Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell (2005) 6.86
Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature (2009) 4.12
FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling, controls Smad4 monoubiquitination. Cell (2009) 4.11
Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res (2007) 3.92
SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature (2011) 3.69
Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases. EMBO J (2011) 3.06
MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene (2004) 2.62
Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood (2010) 2.61
An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res (2000) 2.47
MCL1 transgenic mice exhibit a high incidence of B-cell lymphoma manifested as a spectrum of histologic subtypes. Blood (2001) 2.44
Deubiquitinases in cancer: new functions and therapeutic options. Oncogene (2011) 2.08
Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. Cancer Res (2010) 2.05
Mcl-1. Int J Biochem Cell Biol (2005) 1.96
Chemotherapeutic approaches for targeting cell death pathways. Oncologist (2006) 1.70
Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737. Mol Cancer Ther (2009) 1.42
Targeting signal transducer and activator of transcription signaling pathway in leukemias. J Clin Oncol (2009) 1.40
Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737. Clin Cancer Res (2008) 1.35
Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis. Blood (2011) 1.32
Emerging Bcl-2 inhibitors for the treatment of cancer. Expert Opin Emerg Drugs (2010) 1.32
Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity. Cancer Res (2000) 1.30
RNA silencing of Mcl-1 enhances ABT-737-mediated apoptosis in melanoma: role for a caspase-8-dependent pathway. PLoS One (2009) 1.28
Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737. Clin Cancer Res (2011) 1.27
Acquired activation of the Akt/cyclooxygenase-2/Mcl-1 pathway renders lung cancer cells resistant to apoptosis. Mol Pharmacol (2009) 1.18
Ubiquitin-like sequence in ASK1 plays critical roles in the recognition and stabilization by USP9X and oxidative stress-induced cell death. Mol Cell (2009) 1.16
Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells. Blood (2007) 1.14
Endogenous Noxa Determines the Strong Proapoptotic Synergism of the BH3-Mimetic ABT-737 with Chemotherapeutic Agents in Human Melanoma Cells. Transl Oncol (2009) 1.09
Selective induction of cell death in melanoma cell lines through targeting of Mcl-1 and A1. PLoS One (2012) 0.99
TRAIL-activated stress kinases suppress apoptosis through transcriptional upregulation of MCL-1. Cell Death Differ (2010) 0.94
Mcl1 becomes ubiquitin-ous: new opportunities to antagonize a pro-survival protein. Cell Res (2010) 0.93
A novel small molecule deubiquitinase inhibitor blocks Jak2 signaling through Jak2 ubiquitination. Cell Signal (2011) 0.92
Up-regulation of Bcl-xl by hepatocyte growth factor in human mesothelioma cells involves ETS transcription factors. Am J Pathol (2009) 0.88
Bcl-xL antisense oligonucleotide and cisplatin combination therapy extends survival in SCID mice with established mesothelioma xenografts. Int J Cancer (2008) 0.87
DUB-le Trouble for Cell Survival. Cancer Cell (2010) 0.84
Bcl-xL and Mcl-1 are involved in prevention of in vitro apoptosis in rat late-stage erythroblasts derived from bone marrow. J Toxicol Sci (2012) 0.79
Molecular identification of the CRAC channel by altered ion selectivity in a mutant of Orai. Nature (2006) 7.22
Management of primary pulmonary artery sarcomas. Ann Thorac Surg (2009) 3.37
Morbidity and mortality after benign prostatic hyperplasia surgery: data from the American College of Surgeons national surgical quality improvement program. J Endourol (2014) 2.78
Store-dependent and -independent modes regulating Ca2+ release-activated Ca2+ channel activity of human Orai1 and Orai3. J Biol Chem (2008) 2.75
Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg (2004) 2.18
A functional single-nucleotide polymorphism in the TRPC6 gene promoter associated with idiopathic pulmonary arterial hypertension. Circulation (2009) 2.17
Treatment outcomes of resected esophageal cancer. Ann Surg (2002) 2.03
Use of aprotinin in extrapleural pneumonectomy: effect on hemostasis and incidence of complications. Ann Thorac Surg (2007) 2.01
Intergenic transcription and developmental regulation of cardiac myosin heavy chain genes. Am J Physiol Heart Circ Physiol (2007) 1.73
Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. J Thorac Cardiovasc Surg (2002) 1.64
Enhancing TRAIL-induced apoptosis by Bcl-X(L) siRNA. Cancer Biol Ther (2005) 1.61
Intergenic bidirectional promoter and cooperative regulation of the IIx and IIb MHC genes in fast skeletal muscle. Am J Physiol Regul Integr Comp Physiol (2008) 1.57
A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes. Biochem Pharmacol (2010) 1.56
Cardiac autotransplantation for primary cardiac tumors. Ann Thorac Surg (2006) 1.55
Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg (2007) 1.54
Receptor tyrosine kinase and phosphoinositide-3 kinase signaling in malignant mesothelioma. J Thorac Cardiovasc Surg (2005) 1.49
Bcl2/bcl-xL inhibitor engenders apoptosis and increases chemosensitivity in mesothelioma. Cancer Biol Ther (2007) 1.49
Extended surgical staging for potentially resectable malignant pleural mesothelioma. Ann Thorac Surg (2005) 1.49
Postoperative pulmonary complications after preoperative chemoradiation for esophageal carcinoma: correlation with pulmonary dose-volume histogram parameters. Int J Radiat Oncol Biol Phys (2003) 1.45
Endoscopic ultrasound after preoperative chemoradiation can help identify patients who benefit maximally after surgical esophageal resection. Am J Gastroenterol (2004) 1.43
A novel method for the management of post-thyroidectomy or parathyroidectomy hematoma: a single-institution experience after over 4,000 central neck operations. World J Surg (2014) 1.38
Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys (2007) 1.28
Apoptotic signaling induces hyperpermeability following hemorrhagic shock. Am J Physiol Heart Circ Physiol (2007) 1.23
Incidence of major pulmonary morbidity after pneumonectomy: association with timing of smoking cessation. Ann Thorac Surg (2002) 1.18
Role of Wnt/β-catenin signaling in drug resistance of pancreatic cancer. Curr Pharm Des (2012) 1.15
Prospective randomized study evaluating a biodegradable polymeric sealant for sealing intraoperative air leaks that occur during pulmonary resection. Ann Thorac Surg (2004) 1.13
Long-term outcome of phase II trial evaluating chemotherapy, chemoradiotherapy, and surgery for locoregionally advanced esophageal cancer. Int J Radiat Oncol Biol Phys (2003) 1.07
Angiopoietin-1 inhibits intrinsic apoptotic signaling and vascular hyperpermeability following hemorrhagic shock. Am J Physiol Heart Circ Physiol (2008) 1.04
The novel BH3 α-helix mimetic JY-1-106 induces apoptosis in a subset of cancer cells (lung cancer, colon cancer and mesothelioma) by disrupting Bcl-xL and Mcl-1 protein-protein interactions with Bak. Mol Cancer (2013) 1.04
Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys (2003) 1.03
Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activity. J Med Chem (2012) 1.03
Vitamin D binding protein-macrophage activating factor directly inhibits proliferation, migration, and uPAR expression of prostate cancer cells. PLoS One (2010) 1.03
Benign emptying of the postpneumonectomy space. Ann Thorac Surg (2011) 1.02
Implementation of a surgical safety checklist: impact on surgical team perspectives. Ochsner J (2013) 1.01
Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain. Bioorg Med Chem Lett (2011) 1.00
Disruption of Myc-Max heterodimerization with improved cell-penetrating analogs of the small molecule 10074-G5. Oncotarget (2013) 1.00
The risk of second primary tumors after resection of stage I nonsmall cell lung cancer. Ann Thorac Surg (2003) 0.99
Chondrosarcoma of the thorax. Sarcoma (2011) 0.99
Relaxation of the rigid backbone of an oligoamide-foldamer-based α-helix mimetic: identification of potent Bcl-xL inhibitors. Org Biomol Chem (2012) 0.98
Mutation in acetylcholinesterase1 associated with triazophos resistance in rice stem borer, Chilo suppressalis (Lepidoptera: Pyralidae). Biochem Biophys Res Commun (2008) 0.98
Pharmacophore identification of c-Myc inhibitor 10074-G5. Bioorg Med Chem Lett (2012) 0.98
β-Catenin dynamics in the regulation of microvascular endothelial cell hyperpermeability. Shock (2012) 0.97
Malignant pleural mesothelioma--an update. Int J Occup Environ Health (2004) 0.97
Single-incision laparoscopic appendectomy versus traditional three-port laparoscopic appendectomy: an analysis of outcomes at a single institution. Surg Endosc (2013) 0.97
Explaining physicians' use of EMR systems and performance in the shakedown phase. J Am Med Inform Assoc (2011) 0.97
Protein disregulation in red blood cell membranes of type 2 diabetic patients. Biochem Biophys Res Commun (2003) 0.96
Promising early local control of malignant pleural mesothelioma following postoperative intensity modulated radiotherapy (IMRT) to the chest. Cancer J (2004) 0.96
Comparison of outcomes for single-incision laparoscopic inguinal herniorrhaphy and traditional three-port laparoscopic herniorrhaphy at a single institution. Surg Endosc (2013) 0.95
Bcl-XL small interfering RNA suppresses the proliferation of 5-fluorouracil-resistant human colon cancer cells. Mol Cancer Ther (2005) 0.95
Structurally simple, potent, Plasmodium selective farnesyltransferase inhibitors that arrest the growth of malaria parasites. J Med Chem (2006) 0.95
Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications. J Thorac Cardiovasc Surg (2005) 0.94
Protein recognition and denaturation by self-assembling fragments on a DNA quadruplex scaffold. Angew Chem Int Ed Engl (2007) 0.94
Intensity-modulated radiotherapy following extrapleural pneumonectomy for the treatment of malignant mesothelioma: clinical implementation. Int J Radiat Oncol Biol Phys (2003) 0.92
Surgical care improvement project and surgical site infections: can integration in the surgical safety checklist improve quality performance and clinical outcomes? J Surg Res (2013) 0.91
Transcriptome Analysis and Screening for Potential Target Genes for RNAi-Mediated Pest Control of the Beet Armyworm, Spodoptera exigua. PLoS One (2013) 0.90
Design, synthesis, and in vitro characterization of novel hybrid peptidomimetic inhibitors of STAT3 protein. Bioorg Med Chem (2010) 0.90
Prognosis significance of HER-2/neu overexpression/amplification in Chinese patients with curatively resected gastric cancer after the ToGA clinical trial. World J Surg Oncol (2012) 0.90
17beta-estradiol mediated protection against vascular leak after hemorrhagic shock: role of estrogen receptors and apoptotic signaling. Shock (2010) 0.89
Primary lymphoepithelioma of the esophagus. Ann Thorac Surg (2003) 0.89
Long-segment, supercharged, pedicled jejunal flap for total esophageal reconstruction. J Thorac Cardiovasc Surg (2005) 0.89
Preoperative chemoradiotherapy prior to esophagectomy in elderly patients is not associated with increased morbidity. Ann Thorac Surg (2005) 0.88
Alpha-lipoic acid attenuates hemorrhagic shock-induced apoptotic signaling and vascular hyperpermeability. Shock (2008) 0.88
Chromatography-free entry to substituted salicylonitriles: Mitsunobu-triggered domino reactions of salicylaldoximes. J Org Chem (2014) 0.88
Structural basis for binding and selectivity of antimalarial and anticancer ethylenediamine inhibitors to protein farnesyltransferase. Chem Biol (2009) 0.88
Up-regulation of Bcl-xl by hepatocyte growth factor in human mesothelioma cells involves ETS transcription factors. Am J Pathol (2009) 0.88
Recognition of solvent exposed protein surfaces using anthracene derived receptors. Org Biomol Chem (2006) 0.88
Bcl-xL antisense oligonucleotide and cisplatin combination therapy extends survival in SCID mice with established mesothelioma xenografts. Int J Cancer (2008) 0.87
Amphipathic α-helix mimetics based on a 1,2-diphenylacetylene scaffold. Org Lett (2013) 0.87
The impact of MRSA colonization on surgical site infection following major gastrointestinal surgery. J Gastrointest Surg (2012) 0.86
Coordination complex SH2 domain proteomimetics: an alternative approach to disrupting oncogenic protein-protein interactions. Chem Commun (Camb) (2009) 0.85
Molecular pathogenesis of malignant mesothelioma. Expert Rev Mol Med (2012) 0.85
Surgical Safety Checklist compliance: a job done poorly! J Am Coll Surg (2013) 0.85
STAT3 activity is necessary and sufficient for the development of immune-mediated myocarditis in mice and promotes progression to dilated cardiomyopathy. EMBO Mol Med (2013) 0.85
Cyclosporine A prevents vascular hyperpermeability after hemorrhagic shock by inhibiting apoptotic signaling. J Trauma (2009) 0.85
Synthesis and in vitro evaluation of gabapentin prodrugs that target the human apical sodium-dependent bile acid transporter (hASBT). J Pharm Sci (2010) 0.85
Associations of protein 4.2 with band 3 and ankyrin. Mol Cell Biochem (2006) 0.84
Suppressed expression of LDHB promotes pancreatic cancer progression via inducing glycolytic phenotype. Med Oncol (2015) 0.83
Role of β-catenin in regulating microvascular endothelial cell hyperpermeability. J Trauma (2011) 0.83
Lymphatic muscle cells in rat mesenteric lymphatic vessels of various ages. Lymphat Res Biol (2013) 0.83
The role of Bcl-2 family members in non-small cell lung cancer. Semin Thorac Cardiovasc Surg (2004) 0.83
17beta-estradiol mediates protection against microvascular endothelial cell hyperpermeability. Am J Surg (2009) 0.83
Antisense oligonucleotides directed at the bcl-xl gene product augment chemotherapy response in mesothelioma. Mol Cancer Ther (2004) 0.83
An activatable multimodal/multifunctional nanoprobe for direct imaging of intracellular drug delivery. Biomaterials (2011) 0.83